Open AccessEarly initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
Author(s) -
Song Chelsey Chenxi,
Brown Andrew,
Winstead Ryan,
Yakubu Idris,
Demehin Moses,
Kumar Dhiren,
Gupta Gaurav
Publication year - 2021
Publication title -
endocrinology, diabetes and metabolism
Language(s) - English
Resource type - Journals
ISSN - 2398-9238
DOI - 10.1002/edm2.185
Subject(s) - medicine , urinary system , immunosuppression , hypomagnesemia , renal function , kidney transplant , diabetes mellitus , population , kidney transplantation , retrospective cohort study , kidney , urology , gastroenterology , endocrinology , chemistry , environmental health , magnesium , organic chemistry
Abstract There is a paucity of data on the use of SGLT2 inhibitors on outcomes in kidney transplant recipients. There may be concern in initiating these agents, especially within the first year post‐transplant when renal function is more labile and immunosuppression more intense, due to a presumed high risk of urinary infections and acute kidney injury. This is a retrospective study on 50 kidney transplant recipients, half of whom were started on therapy within the first year of transplant. Over a follow‐up period of 6 months, overall patients had a statistically significant improvement in weight by −2.95 kg [SD 3.54, P = <.0001 (CI: 3.53, 1.50)] as well as hypomagnesemia 0.13 [SD 1.73, P = .0004 (CI: 0.06, 0.20)]. Overall insulin usage declined by −3.7 units [SD 22.8, P = .17]. 14% of patients had at least one urinary tract infection although this rate is not different (~20%) than that reported historically in this high‐risk population.